Harvard Bioscience Inc. (NASDAQ:HBIO) saw unusually-high trading volume on Thursday . Approximately 161,338 shares traded hands during trading, an increase of 115% from the previous session’s volume of 75,177 shares.The stock last traded at $2.95 and had previously closed at $2.99.

Separately, Zacks Investment Research downgraded shares of Harvard Bioscience from a “hold” rating to a “sell” rating in a research note on Thursday, May 5th.

The firm’s market cap is $99.14 million. The company has a 50-day moving average of $3.11 and a 200-day moving average of $3.00.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.03 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.03. The company had revenue of $26.10 million for the quarter, compared to the consensus estimate of $26.60 million. On average, analysts predict that Harvard Bioscience Inc. will post $0.18 EPS for the current fiscal year.

An institutional investor recently raised its position in Harvard Bioscience stock. Glacier Peak Capital LLC increased its position in shares of Harvard Bioscience Inc. (NASDAQ:HBIO) by 6.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 452,258 shares of the company’s stock after buying an additional 27,514 shares during the period. Harvard Bioscience comprises 1.0% of Glacier Peak Capital LLC’s holdings, making the stock its 27th largest position. Glacier Peak Capital LLC owned about 1.33% of Harvard Bioscience worth $1,569,000 at the end of the most recent quarter.

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.